Photo by nci from unsplash
Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies (PCSK9i) have been shown prevent cardiovascular disease events in patients with atherosclerotic cardiovascular disease (ASCVD). Analyzing the characteristics of patients who initiate and… Click to show full abstract
Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies (PCSK9i) have been shown prevent cardiovascular disease events in patients with atherosclerotic cardiovascular disease (ASCVD). Analyzing the characteristics of patients who initiate and do not initiate a PCSK9i may identify
Keywords:
veterans according;
pcsk9 inhibitor;
inhibitor initiation;
according 2018;
among veterans;
initiation among
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!